Precision Medicine in Oncology® | Specialty

Emerging Therapies in Metastatic Breast Cancer

November 15th 2012

Chemotherapy in Advanced Breast Cancer

November 15th 2012

Management of Metastatic Breast Cancer, Part II

November 15th 2012

Improving the Management of Metastatic Breast Cancer, Part I

November 15th 2012

NewYork-Presbyterian/Columbia & Cornell Cancer Program: Collaborating for Advances in Research and Patient Care

November 13th 2012

In September 2012 the new joint Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital was established, bringing together basic, translational, and clinical researchers to operate within a vast, collaborative infrastructure.

In Breast Cancer, Targeted Agents Boost Hormonal Therapies

November 12th 2012

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

How Payers and Oncologists Really Feel About Clinical Pathways

November 6th 2012

Stakeholders weigh in on evidence-based pathway approach designed to decrease practice variation, improve outcomes, and reduce cost.

Dr. Sekulic on Vismodegib for Basal-Cell Nevus Syndrome

November 6th 2012

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.

Overcoming Genetic Transformation in Multiple Myeloma

November 6th 2012

The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.

Five PD-1-Related Questions for Suzanne L. Topalian, MD

November 5th 2012

Suzanne L. Topalian, MD, has led clinical development of monoclonal antibodies to treat patients with melanoma and other solid tumors, including those targeting the PD-1 T cell co-receptor.

Amid Setbacks, Efforts to Target Aurora Kinases Persist

November 1st 2012

The development of targeted agents aimed at aurora kinases has proceeded slowly, and the future may lie in combination therapies.

Potential Biomarker for Response to Bevacizumab in Colorectal Cancer Identified

October 25th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Tracking the Oncology Pipeline: Developments From ESMO

October 25th 2012

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

October 22nd 2012

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

City of Hope: Boldly Traversing the "Valley of Death"

October 19th 2012

Founded in 1913 as a tuberculosis sanatorium, City of Hope today enjoys a reputation as a leading research, treatment, and education center for those with cancer, diabetes, and other life-threatening diseases.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

October 2012: Trials in Progress

October 18th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Putting the Genome to Work in Breast Cancer

October 18th 2012

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Evolving Biologic Diversity Generates New Challenges

October 16th 2012

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.